A platelet cover-up

Blood

Volumn 122, Issue 3, 2013, Pages 307-309

  Arnold, Donald M ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; THROMBOCYTE ANTIGEN; 1A ALLOANTIGEN, HUMAN; MONOCLONAL ANTIBODY;

BRAIN HEMORRHAGE; FETUS; HEMOLYSIS; HUMAN; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTOPENIA; ANIMAL; BLOOD; FEMALE; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NOTE; PREGNANCY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, HUMAN PLATELET; BLOOD PLATELETS; FEMALE; HUMANS; ISOANTIBODIES; MOLECULAR TARGETED THERAPY; PREGNANCY; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84884627489     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-501213     Document Type: Review

References (15)

1. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
2. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-2323.
3. Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA. 2001;98(12):6905-6910. (Pubitemid 32538315)
4. Caccuri F, Giagulli C, Bugatti A, et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci USA. 2012;109(36):14580-14585.
5. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110(8):2838-2845. (Pubitemid 350006936)
6. Bollard CM, Gottschalk S, Helen Huls M, Leen AM, Gee AP, Rooney CM. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virusassociated lymphoma. Cytotherapy. 2011;13(5):518-522.
7. Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol. 2009;20(3):413-424.
8. Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem. 2011;18(21):3136-3155.
9. Bakchoul T, Greinacher A, Sachs UJ, et al. Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody: towards targeted treatment of fetal-alloimmune thrombocytopenia. Blood. 2013;122(3):321-327.
10. Kamphuis MM, Paridaans N, Porcelijn L, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG. 2010; 117(11):1335-1343.
11. Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica. 2008; 93(6):870-877. (Pubitemid 351821723)
12. Bowman J. Thirty-five years of Rh prophylaxis. Transfusion. 2003;43(12):1661-1666. (Pubitemid 37518071)
13. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007; 110(3):833-839. (Pubitemid 47267418)
14. Berkowitz RL, Kolb EA, McFarland JG, Wissert M, Primani A, Lesser M, Bussel JB. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol. 2006;107(1): 91-96.
15. Ghevaert C, Wilcox DA, Fang J, Armour KL, Clark MR, Ouwehand WH, Williamson LM. Developing recombinant HPA-1a-specific antibodies with abrogated Fcγ receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J Clin Invest. 2008;118(8):2929-2938.